Compare RDW & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | HRMY |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | 1410 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | RDW | HRMY |
|---|---|---|
| Price | $9.72 | $35.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $13.71 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 14.0M | 798.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $41.68 | $19.75 |
| Revenue Next Year | $20.25 | $12.88 |
| P/E Ratio | ★ N/A | $64.73 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $4.87 | $25.52 |
| 52 Week High | $26.64 | $40.87 |
| Indicator | RDW | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 50.15 |
| Support Level | $7.87 | $35.05 |
| Resistance Level | $10.43 | $35.47 |
| Average True Range (ATR) | 0.74 | 1.43 |
| MACD | 0.21 | -0.10 |
| Stochastic Oscillator | 68.11 | 62.32 |
Redwire Corp is an integrated space and defense technology company focused on technologies including aerospace infrastructure, autonomous systems and multi-domain operations, leveraging digital engineering and artificial intelligence automation. The Company develops and provides mission critical solutions based on space and defense technology platform offerings for government, commercial and civil customers through both short- and long-duration projects. These include technologies and production capability for next-generation spacecraft, large space infrastructure, microgravity capabilities, combat autonomous systems, optical sensors and radio frequency payloads that provide intelligence, surveillance, and reconnaissance capabilities for U.S. and allied nations across multiple domains.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.